监管机构与临床可接受性:医生对药品安全警告的回应
该研究通过半结构化定性访谈,调查美国波士顿和澳大利亚的40名初级保健医生、内分泌科医生及其他全科专科医生,探讨影响监管安全警告使用的因素。研究发现不确定性、信任和临床权威是影响警告使用的关键因素,监管机构虽被视为权威但缺乏临床权威,医生会结合其他可信来源验证监管信息。美国医生对其国家监管机构上市后安全角色的认知高于澳大利亚医生。
要点
- 监管警告的接收和使用可能不理想,受不确定性、信任和临床权威影响。
- 医生会结合证据、专家意见和临床经验等可信来源验证监管信息。
- 向患者传达风险受不确定性影响,医生需根据患者健康素养调整信息。
核心结论
- 药品安全警告可能未被最优接收或使用,监管机构应考虑提高信任、临床相关性和可及性的策略。
研究设计与样本
- 对40名初级保健医生、内分泌科医生和其他全科专科医生进行半结构化定性访谈,地点为美国波士顿和澳大利亚。
主要发现
- 不确定性、信任和临床权威是影响监管警告使用的因素。
- 监管机构被视为权威机构但缺乏临床权威,医生用其他可信来源验证监管信息。
- 专科医生通过专业文献获知药物安全问题,用证据和临床共识形成意见。
- 初级保健医生依赖媒体和「临床小道消息」等便捷信息源获取信息,依赖同事、专科医生和经验解读。
- 美国医生对其国家监管机构上市后安全角色的认知高于澳大利亚医生。
临床怎么用
- 临床医生应结合证据、专家意见和临床经验验证监管安全警告。
- 向患者传达风险时需考虑不确定性,并根据患者健康素养和信息需求调整沟通。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Medicines regulators issue post-market safety warnings to advise of newly uncovered risks, but with mixed impacts. We aimed to identify factors influencing the use of regulatory warnings by primary care and specialist physicians in the US and Australia. METHODS: Semi-structured qualitative interviews were carried out with 40 primary care physicians, endocrinologists and other generalist specialists in Boston (USA) and Australia. Coding and analysis were performed inductively and iteratively to identify and examine key factors. Analysis centred around four areas: physicians' awareness of drug safety information, preferred information sources, opinion-forming and sharing of information with patients. RESULTS: Uncertainty, trust and clinical authority emerged as factors influencing use of advisories. Although regulators were trusted as authoritative institutions, they appeared to lack clinical authority, and physicians validated regulatory information against other trusted sources including evidence, expert opinion and experience. Specialists became aware of drug safety issues through specialised literature, using evidence and clinical consensus to form opinions. Primary care physicians, fielding high volumes of information, relied on convenient, accessible information sources including the media and the "clinical grapevine" for awareness, and on clinical colleagues, specialists and experience for interpretation. Communicating risk to patients was complicated by uncertainty; physicians tailored information to patients' health literacy and information needs. US physicians were more aware of their national regulator's post-market safety role than Australian physicians of theirs. CONCLUSION: Drug safety warnings may not be optimally received or used. Regulators should consider strategies that increase trust, clinical relevance and accessibility, and address physicians' needs in communicating risk to patients.
引用
- Bhasale AL, Sarpatwari A, Lipworth W, et al. Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings. Br J Clin Pharmacol. 2021. PMID: 34337777. doi:10.1111/bcp.15007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。